## Jordan D Dimitrov

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1694667/publications.pdf

Version: 2024-02-01

147726 189801 3,119 108 31 50 citations g-index h-index papers 115 115 115 3696 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome. Blood, 2013, 122, 282-292.	0.6	207
2	Molecular basis for bacterial peptidoglycan recognition by LysM domains. Nature Communications, 2014, 5, 4269.	5.8	167
3	Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome. Blood, 2009, 114, 2837-2845.	0.6	140
4	Intravascular hemolysis activates complement via cell-free heme and heme-loaded microvesicles. JCI Insight, 2018, 3, .	2.3	135
5	Heme: Modulator of Plasma Systems in Hemolytic Diseases. Trends in Molecular Medicine, 2016, 22, 200-213.	3.5	126
6	Antibody Polyreactivity in Health and Disease: Statu Variabilis. Journal of Immunology, 2013, 191, 993-999.	0.4	100
7	P-selectin drives complement attack on endothelium during intravascular hemolysis in TLR-4/heme-dependent manner. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 6280-6285.	3.3	90
8	Antibodies Use Heme as a Cofactor to Extend Their Pathogen Elimination Activity and to Acquire New Effector Functions. Journal of Biological Chemistry, 2007, 282, 26696-26706.	1.6	81
9	Ferrous Ions and Reactive Oxygen Species Increase Antigen-binding and Anti-inflammatory Activities of Immunoglobulin G. Journal of Biological Chemistry, 2006, 281, 439-446.	1.6	72
10	Intravenous immunoglobulin induces proliferation and immunoglobulin synthesis from B cells of patients with common variable immunodeficiency: A mechanism underlying the beneficial effect of IVIg in primary immunodeficiencies. Journal of Autoimmunity, 2011, 36, 9-15.	3.0	67
11	The interaction between factor H and VWF increases factor H cofactor activity and regulates VWF prothrombotic status. Blood, 2014, 123, 121-125.	0.6	63
12	Breaking the law: unconventional strategies for antibody diversification. Nature Reviews Immunology, 2019, 19, 355-368.	10.6	63
13	Natural Antibodies: from First-Line Defense Against Pathogens to Perpetual Immune Homeostasis. Clinical Reviews in Allergy and Immunology, 2020, 58, 213-228.	2.9	60
14	TCR Stimulation Drives Cleavage and Shedding of the ITIM Receptor CD31. Journal of Immunology, 2010, 184, 5485-5492.	0.4	58
15	Heme Interacts with C1q and Inhibits the Classical Complement Pathway. Journal of Biological Chemistry, 2011, 286, 16459-16469.	1.6	56
16	Exposure of IgG to an acidic environment results in molecular modifications and in enhanced protective activity in sepsis. FEBS Journal, 2010, 277, 3039-3050.	2.2	53
17	Inflammation-induced enhancement of IgG immunoreactivity. Inflammation Research, 2008, 57, 1-3.	1.6	52
18	Important parameters for evaluation of antibody avidity by immunosorbent assay. Analytical Biochemistry, 2011, 418, 149-151.	1.1	46

#	Article	IF	CITATIONS
19	Conformational Plasticity in Broadly Neutralizing HIV-1 Antibodies Triggers Polyreactivity. Cell Reports, 2018, 23, 2568-2581.	2.9	46
20	Factor VIII Hydrolysis Mediated by Anti-Factor VIII Autoantibodies in Acquired Hemophilia. Journal of Immunology, 2008, 180, 7714-7720.	0.4	45
21	Functional Characterization of Autoantibodies against Complement Component C3 in Patients with Lupus Nephritis. Journal of Biological Chemistry, 2015, 290, 25343-25355.	1.6	44
22	Heme induces human and mouse platelet activation through C-type-lectin-like receptor-2. Haematologica, 2021, 106, 626-629.	1.7	44
23	Regulation of immune responses to protein therapeutics by transplacental induction of T cell tolerance. Science Translational Medicine, 2015, 7, 275ra21.	5.8	43
24	Characterization of Renal Injury and Inflammation in an Experimental Model of Intravascular Hemolysis. Frontiers in Immunology, 2018, 9, 179.	2.2	41
25	Impact of Antigen Density on the Binding Mechanism of IgG Antibodies. Scientific Reports, 2017, 7, 3767.	1.6	40
26	Proteolytic antibodies activate factor IX in patients with acquired hemophilia. Blood, 2011, 117, 2257-2264.	0.6	38
27	Heme Drives Susceptibility of Glomerular Endothelium to Complement Overactivation Due to Inefficient Upregulation of Heme Oxygenase-1. Frontiers in Immunology, 2018, 9, 3008.	2.2	36
28	Intravenous immunoglobulin induces IL-4 in human basophils by signaling through surface-bound IgE. Journal of Allergy and Clinical Immunology, 2019, 144, 524-535.e8.	1.5	36
29	Potent human broadly neutralizing antibodies to hepatitis B virus from natural controllers. Journal of Experimental Medicine, 2020, 217, .	4.2	34
30	Potent human broadly SARS-CoV-2–neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2. Journal of Experimental Medicine, 2022, 219, .	4.2	34
31	Transition towards antigen-binding promiscuity of a monospecific antibody. Molecular Immunology, 2007, 44, 1854-1863.	1.0	33
32	Metrics: journal's impact factor skewed by a single paper. Nature, 2010, 466, 179-179.	13.7	33
33	Iron Ions and Haeme Modulate the Binding Properties of Complement Subcomponent C1q and of Immunoglobulins. Scandinavian Journal of Immunology, 2007, 65, 230-239.	1.3	32
34	Sequence features of variable region determining physicochemical properties and polyreactivity of therapeutic antibodies. Molecular Immunology, 2019, 112, 338-346.	1.0	32
35	Intravenous immunoglobulins exposed to heme (heme IVIG) are more efficient than IVIG in attenuating autoimmune diabetes. Clinical Immunology, 2011, 138, 162-171.	1.4	30
36	Development of inhibitory antibodies to therapeutic factor VIII in severe hemophilia A is associated with microsatellite polymorphisms in the HMOX1 promoter. Haematologica, 2013, 98, 1650-1655.	1.7	29

#	Article	IF	CITATIONS
37	Induction of heme oxygenase-1 in factor VIII–deficient mice reduces the immune response to therapeutic factor VIII. Blood, 2010, 115, 2682-2685.	0.6	28
38	Antibody Polyspecificity. Advances in Experimental Medicine and Biology, 2012, 750, 213-226.	0.8	28
39	Prevalence and Gene Characteristics of Antibodies with Cofactor-induced HIV-1 Specificity. Journal of Biological Chemistry, 2015, 290, 5203-5213.	1.6	28
40	Identification of target antigens of selfâ€reactive IgG in intravenous immunoglobulin preparations. Proteomics, 2009, 9, 2253-2262.	1.3	27
41	Heterogeneous antigen recognition behavior of induced polyspecific antibodies. Biochemical and Biophysical Research Communications, 2010, 398, 266-271.	1.0	27
42	A Cellular Viewpoint of Anti-FVIII Immune Response in Hemophilia A. Clinical Reviews in Allergy and Immunology, 2009, 37, 105-113.	2.9	24
43	Antibody-mediated catalysis: Induction and therapeutic relevance. Autoimmunity Reviews, 2013, 12, 648-652.	2.5	24
44	Intravenous Immunoglobulin with Enhanced Polyspecificity Improves Survival in Experimental Sepsis and Aseptic Systemic Inflammatory Response Syndromes. Molecular Medicine, 2015, 21, 1002-1010.	1.9	24
45	Materno-Fetal Transfer of Preproinsulin Through the Neonatal Fc Receptor Prevents Autoimmune Diabetes. Diabetes, 2015, 64, 3532-3542.	0.3	24
46	Hydrolysis of Coagulation Factors by Circulating IgG Is Associated with a Reduced Risk for Chronic Allograft Nephropathy in Renal Transplanted Patients. Journal of Immunology, 2008, 180, 8455-8460.	0.4	22
47	Longitudinal and Integrative Biomodeling of Effector and Memory Immune Compartments after Inactivated Influenza Vaccination. Journal of Immunology, 2013, 191, 623-631.	0.4	21
48	HIV-1 Envelope Recognition by Polyreactive and Cross-Reactive Intestinal B Cells. Cell Reports, 2019, 27, 572-585.e7.	2.9	21
49	Heme binds to factor VIII and inhibits its interaction with activated factor IX. Journal of Thrombosis and Haemostasis, 2012, 10, 1062-1071.	1.9	20
50	A Cryptic Polyreactive Antibody Recognizes Distinct Clades of HIV-1 Glycoprotein 120 by an Identical Binding Mechanism. Journal of Biological Chemistry, 2014, 289, 17767-17779.	1.6	19
51	Neutralization of Japanese Encephalitis Virus by heme-induced broadly reactive human monoclonal antibody. Scientific Reports, 2015, 5, 16248.	1.6	19
52	Heme oxygenase-1 is dispensable for the anti-inflammatory activity of intravenous immunoglobulin. Scientific Reports, 2016, 6, 19592.	1.6	19
53	Functional variability of antibodies upon oxidative processes. Autoimmunity Reviews, 2008, 7, 574-578.	2.5	18
54	Auditing Protein Therapeutics Management by Professional APCs: Toward Prevention of Immune Responses against Therapeutic Proteins. Journal of Immunology, 2008, 181, 1609-1615.	0.4	18

#	Article	IF	CITATIONS
55	Factor VIIIâ€hydrolyzing IgG in acquired and congenital hemophilia. FEBS Letters, 2009, 583, 2565-2572.	1.3	18
56	Protein destabilizing agents induce polyreactivity and enhanced immunomodulatory activity in IVIg preparations. Autoimmunity, 2009, 42, 365-367.	1.2	17
57	Thermodynamic Analysis of the Interaction of Factor VIII with von Willebrand Factor. Biochemistry, 2012, 51, 4108-4116.	1.2	17
58	Noncanonical Functions of Antibodies. Trends in Immunology, 2020, 41, 379-393.	2.9	17
59	Cofactor-mediated protein promiscuity. Nature Biotechnology, 2009, 27, 892-892.	9.4	16
60	The receptor for advanced glycation end products is a sensor for cellâ€free heme. FEBS Journal, 2021, 288, 3448-3464.	2.2	16
61	Insight into the mechanism of the acquired antibody auto-reactivity. Autoimmunity Reviews, 2008, 7, 410-414.	2.5	15
62	Epitope convergence of broadly HIV-1 neutralizing IgA and IgG antibody lineages in a viremic controller. Journal of Experimental Medicine, 2022, 219, .	4.2	14
63	A human FVIII inhibitor modulates FVIII surface electrostatics at a VWF-binding site distant from its epitope. Journal of Thrombosis and Haemostasis, 2010, 8, 1524-1531.	1.9	13
64	Mechanism and Functional Implications of the Heme-Induced Binding Promiscuity of IgE. Biochemistry, 2015, 54, 2061-2072.	1.2	13
65	Use of cysteine as a spectroscopic probe for determination of heme-scavenging capacity of serum proteins and whole human serum. Journal of Pharmaceutical and Biomedical Analysis, 2019, 172, 311-319.	1.4	13
66	Bortezomib delays the onset of factorÂVIII inhibitors in experimental hemophiliaÂA, but fails to eliminate established antiâ€factorÂVIII IgGâ€producing cells. Journal of Thrombosis and Haemostasis, 2011, 9, 719-728.	1.9	12
67	"Rational Vaccine Design―for HIV Should Take into Account the Adaptive Potential of Polyreactive Antibodies. PLoS Pathogens, 2011, 7, e1002095.	2.1	12
68	Thermodynamic stability contributes to immunoglobulin specificity. Trends in Biochemical Sciences, 2014, 39, 221-226.	3.7	12
69	Potential Predictive Role of Lipid Peroxidation Markers for Type 2 Diabetes in the Adult Tunisian Population. Canadian Journal of Diabetes, 2018, 42, 263-271.	0.4	12
70	Predictive immunogenicity of Refacto $\langle \sup \hat{A}^{\otimes} \langle \sup \rangle \langle \exp \rangle AF \langle \sec \rangle$ . Haemophilia, 2014, 20, 486-492.	1.0	11
71	Relevance of the Materno-Fetal Interface for the Induction of Antigen-Specific Immune Tolerance. Frontiers in Immunology, 2020, 11, 810.	2.2	10
72	Cryptic polyreactivity of IgG expressed by splenic marginal zone B-cell lymphoma. Molecular Immunology, 2014, 60, 54-61.	1.0	9

#	Article	IF	Citations
73	Heme-Exposed Pooled Therapeutic IgG Improves Endotoxemia Survival. Inflammation, 2017, 40, 117-122.	1.7	9
74	Methods for Posttranslational Induction of Polyreactivity of Antibodies. Methods in Molecular Biology, 2017, 1643, 135-145.	0.4	9
75	Harnessing the Therapeutic Potential of †Rogue' Antibodies. Trends in Pharmacological Sciences, 2020, 41, 409-417.	4.0	9
76	Interaction of clinical-stage antibodies with heme predicts their physiochemical and binding qualities. Communications Biology, 2021, 4, 391.	2.0	9
77	Sialylated therapeutic IgG: a sweet remedy for inflammatory diseases?. Nephrology Dialysis Transplantation, 2007, 22, 1301-1304.	0.4	8
78	Anti-inflammatory activity of intravenous immunoglobulin through scavenging of heme. Molecular lmmunology, $2019,111,205-208.$	1.0	8
79	Anti-IgE IgG autoantibodies isolated from therapeutic normal IgG intravenous immunoglobulin induce basophil activation. Cellular and Molecular Immunology, 2020, 17, 426-429.	4.8	8
80	Optimization of casein-based semisynthetic medium for growing of toxigenic Corinebacterium diphtheriae in a fermenter. Canadian Journal of Microbiology, 2004, 50, 821-826.	0.8	7
81	V Region of IgG Controls the Molecular Properties of the Binding Site for Neonatal Fc Receptor. Journal of Immunology, 2020, 205, 2850-2860.	0.4	7
82	How can polyreactive antibodies conquer rapidly evolving viruses?. Trends in Immunology, 2021, 42, 654-657.	2.9	7
83	Functional Changes of Therapeutic Antibodies upon Exposure to Pro-Oxidative Agents. Antibodies, 2022, 11, 11.	1.2	7
84	Kinetics and thermodynamics of interaction of coagulation factor VIII with a pathogenic human antibody. Molecular Immunology, 2009, 47, 290-297.	1.0	6
85	Relationship between natural and heme-mediated antibody polyreactivity. Biochemical and Biophysical Research Communications, 2016, 472, 281-286.	1.0	6
86	Method for identification of heme-binding proteins and quantification of their interactions. Analytical Biochemistry, 2020, 607, 113865.	1.1	5
87	Natural and Induced Antibody Polyreactivity. Anti-Cancer Agents in Medicinal Chemistry, 2015, 15, 1230-1241.	0.9	5
88	Oxidation of factor VIII increases its immunogenicity in mice with severe hemophilia A. Cellular Immunology, 2018, 325, 64-68.	1.4	4
89	Enhanced Pro-apoptotic Effects of Fe(II)-Modified IVIG on Human Neutrophils. Frontiers in Immunology, 2020, 11, 973.	2.2	4
90	Inhibitors of Factor VIII in Hemophilia. New England Journal of Medicine, 2009, 361, 308-310.	13.9	3

#	Article	IF	Citations
91	Stimulation with FITC-labeled antigens confers B cells with regulatory properties. Cellular Immunology, 2020, 355, 104151.	1.4	3
92	Heme: driver of erythrocyte elimination. Blood, 2021, 138, 1092-1094.	0.6	3
93	Induced antigen-binding polyreactivity in human serum IgA. Immunobiology, 2022, 227, 152213.	0.8	3
94	Anaerobic Bacteriology in 75 Cases of Thoracic Empyema in Sofia, Bulgaria. Anaerobe, 2000, 6, 81-85.	1.0	2
95	Molecular composition of diphtheria toxoid produced using semi-synthetic and meat extract-based broths. World Journal of Microbiology and Biotechnology, 2004, 20, 211-217.	1.7	2
96	Thermodynamic Analysis of Hepatitis C Virus Vitality in Syringes. Journal of Infectious Diseases, 2011, 203, 1696-1697.	1.9	2
97	Comment on Enhancement of the Catalytic Activity of a 27 kDa Subtilisin-like Enzyme from Bacillus amyloliquefaciens CH51 by in Vitro Mutagenesis. Journal of Agricultural and Food Chemistry, 2012, 60, 4170-4172.	2.4	2
98	Gain of function of immunoglobulins after partial unfolding or cofactor binding. Molecular Immunology, 2013, 55, 195-196.	1.0	2
99	Serum or breast milk immunoglobulins mask the selfâ€reactivity of human natural IgG antibodies. Apmis, 2014, 122, 329-340.	0.9	2
100	Methods for Assessment of Interactions of Proteins with Heme: Application for Complement Proteins and Immunoglobulins. Methods in Molecular Biology, 2021, 2227, 227-236.	0.4	2
101	Interaction with 2,4-dinitrophenol correlates with polyreactivity, self-binding, and stability of clinical-stage therapeutic antibodies. Molecular Immunology, 2021, 140, 233-239.	1.0	2
102	Implementation and evaluation of classroom simulation for trainee teacher using second life environments. , 2013, , .		1
103	Aromatic Guanylhydrazones for the Control of Heme-Induced Antibody Polyreactivity. ACS Omega, 2019, 4, 20450-20458.	1.6	1
104	Evaluation of Binding Kinetics and Thermodynamics of Antibody–Antigen Interactions and Interactions Involving Complement Proteins. Methods in Molecular Biology, 2021, 2227, 237-247.	0.4	1
105	Atypical hemolytic uremic syndrome – Why the kidney?. Molecular Immunology, 2017, 89, 172-173.	1.0	0
106	Noncanonical antibody strategy for broad and potent neutralization of influenza virus. Cellular and Molecular Immunology, 2021, 18, 1615-1617.	4.8	0
107	Development of Inhibitory Antibodies to Therapeutic Factor VIII in Severe Hemophilia A Is Associated with Microsatellite Polymorphism in the HMOX1 promoter. Blood, 2012, 120, 38-38.	0.6	0
108	Microbial symphony orchestrated by mucosal IgA. Cellular and Molecular Immunology, 2022, , .	4.8	0